Atrial Fibrillation (AF) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Atrial fibrillation (AF) is the most typical sustained cardiac arrhythmia. AF is often associated with other chronic cardiovascular conditions, including hypertension and heart failure, and long-term AF can result in a significantly raised risk of stroke. AF causes an estimated 15% of all strokes, and it accounts for one-third of strokes in individuals aged 65 years or older. AF is a complex disease with only a partly elucidated pathophysiology; it is the subject of extensive medical research, believing that a complete understanding of AF will yield novel drug therapies with improved effectiveness and safety profiles over current drugs. In keeping with other forms of cardiac arrhythmia, both a triggering factor and a substrate are thought to be required for AF induction; early-stage research has identified several novel targets that have the potential to prevent abnormal impulse formation (the trigger) and help reverse long-term structural and electrical remodeling. Guidelines prepared by the American Heart Association (AHA)/American College of Cardiology (ACC)/European Society of Cardiology (ESC) classify AF into four major categories. Atrial fibrillation (AF) is classified based on its duration and its reversibility into sinus rhythm. The last three categories apply to recurrent AF episodes. The first-detected episode of AF can be symptomatic or self-limiting, and the diagnosing physician may be uncertain about the episode's duration and previous episodes.

 

Atrial fibrillation (AF) prevalence increased from 0.1% among adults younger than 55 to 8.5% in 80 years or older. Approximately 2.12 MN to 2.4 MN US adults is currently diagnosed with AF.

 

The competitive landscape of Atrial Fibrillation (AF) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Atrial Fibrillation (AF) across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Atrial Fibrillation (AF) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Atrial Fibrillation (AF) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Abelacimab       Anthos Therapeutics, Inc.          Phase 2

2          AGN-151607     Allergan            Phase 2

3          AP30663           Acesion Pharma            Phase 2

4          Rivaroxaban      Bayer   Phase 3

5          Apixaban          Pfizer    Phase 3

6          CKD-825           Chong Kun Dang Pharmaceutical           Phase 3

7          Flecainide Acetate         InCarda Therapeutics, Inc.         Phase 2

8          HSY244            Novartis Pharmaceuticals          Phase 2

9          OMT-28            Omeicos Therapeutics GmbH    Phase 2

10        HBI-3000          HUYABIO International, LLC.     Phase 2

Continued